Tunç Akkoç

Prof. Dr. Tunç Akkoç completed his doctoral studies in Pediatric Allergy and Immunology at Marmara University Faculty of Medicine. He was awarded the title of Associate Professor in 2009 and became a Full Professor in 2014. He is currently a faculty member and serves as the Head of the Department of Immunology at Marmara University Faculty of Medicine.

His research focuses on the immunological basis of autoimmune and allergic diseases, mechanisms of immunomodulation and immunotherapy, as well as stem cell and cellular therapies. He has conducted studies on T cell responses in patients with atopic dermatitis in Davos, Switzerland. He also participated in a joint Marie Curie project involving Sweden, Romania, and Turkey, which investigated the relationship between atopic diseases and hygiene. As part of this project, he continued his research in Gothenburg, Sweden.

In recent years, he has concentrated on the immunomodulatory effects of mesenchymal stem cells (MSCs) and their therapeutic potential in the treatment of atopic diseases, Crohn’s disease, and other autoimmune disorders. His research includes both experimental models and clinical studies focusing on stem cell–based therapeutic strategies.

Prof. Dr. Akkoç has authored approximately 120 scientific publications, with over 2,817 citations to date, reflecting his ongoing scientific productivity and contribution to the field.
His group conducts research on the development of antibacterial MSCs, applications of MSCs and exosomes in veterinary medicine, the role of MSC-derived exosomes in wound healing, and stem cell–based approaches in thyroid disorders, inflammatory bowel diseases (IBD), and recurrent pregnancy loss. His laboratory also works on the development of biomaterial-based scaffold systems for regenerative medicine applications.

He is a member of the Stem Cell Working Group of the Turkish Academy of Sciences (TÜBA), and a founding member of the Turkish Society for Stem Cell and Cellular Therapies, where he served as President during the third term.